Comparison of dry mouth in women treated with extended-release formulations of oxybutynin or tolterodine for overactive bladder

International Urology and Nephrology

Volumn 37, Issue 2, 2005, Pages 247-252

  Armstrong, Robert B ^a   Luber, Karl M ^b   Peters, Kenneth M ^c  

^a Ortho McNeil Pharmaceutical Incorporated   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c WILLIAM BEAUMONT HOSPITAL   (United States)

Author keywords

Delayed action preparations; Drug therapy; Female; Muscarinic antagonists; Urinary incontinence; Xerostomia

Indexed keywords

OXYBUTYNIN; TOLTERODINE;

AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG WITHDRAWAL; FEMALE; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MULTICENTER STUDY; OVERACTIVE BLADDER; PARALLEL DESIGN; RANDOMIZED CONTROLLED TRIAL; SUSTAINED RELEASE FORMULATION; XEROSTOMIA;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BENZHYDRYL COMPOUNDS; CRESOLS; DELAYED-ACTION PREPARATIONS; DOUBLE-BLIND METHOD; HUMANS; MANDELIC ACIDS; MIDDLE AGED; MUSCARINIC ANTAGONISTS; PHENYLPROPANOLAMINE; SEVERITY OF ILLNESS INDEX; URINARY INCONTINENCE; XEROSTOMIA;

EID: 25144486221     PISSN: 03011623     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11255-004-4703-7     Document Type: Article

References (19)

1. YE Yarker KL Goa A. Fitton 1995 Oxybutynin: A review of its pharmacodynamic and pharmacokinetic properties, and its therapeutic use in detrusor stability Drugs Aging 6 243-262 7620236
2. R. Appell 1997 Clinical efficacy and safety of tolterodine in the treatment of overactive bladder: A pooled analysis Urology 50 Suppl 90-96 10.1016/S0090-4295(97)00599-2 9426760
3. E Versi R Appell D Mobley et al. 2000 Dry mouth with conventional and controlled-release oxybutynin in urinary incontinence Obstet Gynecol 95 718-721 10.1016/S0029-7844(99)00661-4 10775736
4. L Rentzhog SL Stanton L Cardozo et al. 1998 Efficacy and safety of tolterodine in patients with detrusor instability: A dose-ranging study Br J Urol 81 42-48 9467475
5. TO Närhi JH Meurman A. Ainamo 1999 Xerostomia and hyposalivation: causes, consequences and treatment in the elderly Drugs Aging 15 103-116 10495070
6. FC Astor KL Hanft JO. Ciocon 1999 Xerostomia: A prevalent condition in the elderly Ear Nose Throat J 78 476-479 10429321
7. WJ Loesche J Bromberg MS Terpenning et al. 1995 Xerostomia, xerogenic medications and food avoidances in selected geriatric groups J Am Geriatr Soc 43 401-407 7706631
8. NL Rhodus J. Brown 1990 The association of xerostomia and inadequate intake in older adults J Am Diet Assoc 90 1688-1692 2131338
9. G Sathyan MB Chancellor SK. Gupta 2001 Effect of OROS® controlled-release delivery on the pharmacokinetics and pharmacodynamics of oxybutynin chloride Br J Clin Pharmacol 52 409-417 10.1046/ j.0306-5251.2001.01463.x 11678784
10. RU Anderson D Mobley B Blank et al. 1999 Once daily controlled versus immediate release oxybutynin chloride for urge urinary incontinence J Urol 161 1809-1812 10.1097/00005392-199906000-00020 10332441
11. MB Chancellor RA Appell G Sathyan SK. Gupta 2001 A comparison of the effects on saliva output of oxybutynin chloride and tolterodine tartrate Clin Ther 23 753-760 10.1016/S0149-2918(01)80024-2 11394733
12. P Abrams R Freeman C Anderstrom A. Mattiasson 1998 Tolterodine, a new antimuscarinic agent: As effective but better tolerated than oxybutynin in patients with an overactive bladder Br J Urol 81 801-810 9666761
13. HP Drutz RA Appell D Gleason et al. 1999 Clinical efficacy and safety of tolterodine compared to oxybutynin and placebo in patients with overactive bladder Int Urogynecol J 10 283-289 10.1007/s001929970003
14. RA Appell P Sand R Dmochowski et al. 2001 OBJECT Study Group. Prospective randomized controlled trial of extended-release oxybutynin chloride and tolterodine tartrate in the treatment of overactive bladder: Results of the OBJECT study Mayo Clin Proc 76 358-363 11322350
15. Detrol® tolterodine tartrate tablets prescribing information. Pharmacia & Upjohn Company, Kalamazoo, MI, July, 2002. Available at: http://www.detrolla.com/files/Detrol.pdf. Accessed September 24, 2003.
16. AC Diokno RA Appell PK Sand et al. 2003 Prospective, randomized, double-blind, study of the efficacy and tolerability of the extended-release formulations of oxybutynin and tolterodine for overactive bladder: Results of the OPERA trial Mayo Clin Proc 78 687-695 12934777
17. K Waldeck B Larsson KE. Andersson 1997 Comparison of oxybutynin and its active metabolite, N-desethyl-oxybutynin, in the human detrusor and parotid gland J Urol 157 1093-1097 10.1097/00005392-199703000-00113 9072550
18. J Douchamps F Derenne A Stockis et al. 1988 The pharmacokinetics of oxybutynin in man Eur J Clin Pharmacol 35 515-520 10.1007/BF00558247 3234461
19. SK Gupta G. Sathyan 1999 Pharmacokinetics of an oral once-a-day controlled-release oxybutynin formulation compared with immediate-release oxybutynin J Clin Pharm 39 22-29